ClinicalTrials.gg
Active, not recruitingNCT05086692ABILITY-1Updated Oct 30, 2026

A Beta-only IL-2 ImmunoTherapY Study

A Phase 1/2 interventional study of MDNA11 and Pembrolizumab (KEYTRUDA®) in Advanced Solid Tumor, Unresectable Solid Tumor and Clear Cell Renal Cell Carcinoma, sponsored by Medicenna Therapeutics, Inc.. Active, not recruiting at 25 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Medicenna Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know · 25 judgments

Updated Oct 30, 2026Now Active, not recruitingFirst site in Switzerland+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
160
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,144 studies in Carcinoma, Renal Cell with a site in United States — 154 open to participants now, 278 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.

Planned enrollment
174th of 1,010
160 · median 40
Started
2021
with 52 others
Phase 1/2
147 of 1,144
30 open now
Primary completion
2028-10
later than 206 of 276 live
Registered
915th of 1,144
by date

Among the 1,144 studies in Carcinoma, Renal Cell with a site in United States, this one is the 174th largest by planned enrollment of the 1,010 interventional ones that give a count, is one of 53 that started in 2021, is one of 147 in phase 1/2, reaches primary completion later than 206 of the 276 other live ones, and was the 915th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

154 of the 1,144 studies in Carcinoma, Renal Cell with a site in United States are open now. Recruiting first, the newest first:

149 more — sign in →

All 154 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,144 studies in Carcinoma, Renal Cell with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

Read the detailed description

The study drug, MDNA11, long-acting "beta-only" recombinant interleukin-2 (rIL-2). MDNA11 specifically engineered to overcome the shortcomings of rhIL-2 (aldesleukin) by preferentially activating immune effector cells (CD8+ T- and NK cells) responsible for killing cancer cells, with minimal or no stimulation of immunosuppressive Tregs. It is designed to potentially enhance host immune response and fusion to albumin increases the half-life further avoiding frequent dosing required with rhIL-2.

The study will be conducted at up to 30 clinical sites following regulatory authority and institutional review board / independent ethics committee (IRB/ IEC) approval and completion of informed consent. The study will be conducted in multiple parts:

  • Monotherapy (MDNA11 alone) dose escalation
  • Monotherapy (MDNA11 alone) dose expansion in select tumor types
  • Combination (MDNA11 + pembrolizumab) dose escalation
  • Combination (MDNA11 + pembrolizumab) dose expansion in select tumor types

Approximately 160 patients will be enrolled.

After commencing treatment (first exposure of MDNA11 alone or MDNA11 + pembrolizumab), tumor assessment by CT/MRI will be performed every 8 weeks ± 1 week until immune confirmed progressive disease ("iCPD") by iRECIST, discontinuation of study drug(s), withdrawal of consent or loss to follow-up. Treatment beyond progression may be permitted if criteria are met. Patients can withdraw from participation at any time.

03

Conditions studied

  • Advanced Solid Tumor
  • Unresectable Solid Tumor
  • Clear Cell Renal Cell Carcinoma
  • Triple Negative Breast Cancer
  • Non-Small Cell Lung Cancer Squamous
  • Non-Small Cell Lung Cancer Non-squamous
  • Colorectal Cancer (MSI-H)
  • Gastric Cancer
  • Cervical Cancer
  • Basal Cell Carcinoma
  • Bladder Cancer
  • Merkel Cell Carcinoma
  • Squamous Cell Carcinoma of Head and Neck
  • Cutaneous Squamous Cell Carcinoma
  • Pleural Mesothelioma
  • Esophageal Cancer
  • Endometrial Carcinoma
  • Solid Tumor
  • Solid Tumor, Adult
  • MSI-H Solid Malignant Tumor
  • Cancer With A High Tumor Mutational Burden
  • Epithelial Ovarian Carcinoma
  • Primary Peritoneal Cancer
  • Gastroesophageal Junction (GEJ) Cancer
  • Acral Melanoma
  • Mucosal Melanoma
  • Cutaneous Melanoma
  • DMMR Solid Malignant Tumor
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • MSI-H Cancer
  • DMMR Cancer
  • Pancreas Adenocarcinoma (MSI-H)
  • Skin Cancer
  • Viral Cancer
  • Cervical Cancers
  • Endometrial Cancer

Keywords

  • IL-2
  • IL2
  • Interleukin-2
  • cancer
  • metastatic
  • ccRCC
  • TNBC
  • NSCLC
  • CRC
  • GEJ
  • intrahepatic
  • extrahepatic
  • MCC
  • SCCHN
  • CSCC
  • Gastroesophageal Junction
  • advanced
  • unresectable
  • MSI-H
  • dMMR
  • Microsatellite Instability-High
  • Mismatch Repair Deficient
  • PD-1
  • immunotherapy
  • anti-PD-1
  • BCC
  • RCC
  • HCC
  • Tumor Mutation Burden High
  • TMB-H
  • PDAC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Aged at least 18 years (inclusive at the time of ).
  2. (ECOG) Performance Status of 0 to 1.
  3. Must be able and willing to provide written informed consent prior to start of any study procedures and assessments and must be willing to comply with all study procedures.
  4. or cytologically confirmed locally advanced or solid tumor (see tumor types listed under conditions)
  5. Demonstrated adequate organ function
  6. as per , (RECIST v1.1) and documented by CT and/or MRI.
  7. of ≥ 12 weeks.
  8. Women of (WOCBP) must have a negative pregnancy test at screening and within 72 hours before the first dose of study drug(s). Women must not be breastfeeding.
  9. Agree to use highly effective methods. WOCBP must agree to use highly effective birth control.

Key Exclusion Criteria:

  1. Last administration of prior antitumor therapy:

    • Prior systemic anti-cancer therapy including agents within 4 weeks (could consider shorter interval for kinase inhibitors or other short half-life drugs) prior to start of treatment.
    • Prior radiotherapy within 2 weeks prior to start of treatment or has had a history of radiation pneumonitis. A 1-week is required for palliative radiation (\<2 weeks of radiotherapy) to non-CNS disease.
    • Radiation therapy to the lung that is > 30Gy within 6 months prior to start of treatment.
    • Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to start of treatment. Concomitant participation in an observational study must be discussed on a case-by-case basis with the MM for approval.
  2. Has known active and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of treatment for at least 14 days prior to start of treatment, subject to discussion with MM.
  3. Active (other than the disease under treatment in the study) within the previous 3 years except for curable cancers.
  4. Condition requiring long-term systemic treatment with either corticosteroids > 10 mg daily prednisone equivalent or any other form of therapy within 7 days prior to start of treatment.
  5. active, known or suspected disease, or diseases that can be exacerbated with immunotherapy.
  6. Severe pulmonary, cardiac or other systemic disease.
  7. Known or C virus infection.
  8. Females who are pregnant or lactating or planning to become pregnant during the study.
  9. Has had an allogeneic tissue/solid organ transplant.
  10. Active infection requiring systemic therapy.
  11. Any medical, emotional or psychiatric condition that interfere with the patient's ability to adhere to the protocol
  12. Any other underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug(s) unsafe or obscure the interpretation of toxicity determination or adverse events.
  13. Known severe to any component of study drug(s).
  14. Inability to comply with study and follow up procedures as judged by the Investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    MDNA11

    MDNA11 is a long-acting "beta-only" recombinant interleukin-2 (rIL-2) albumin fusion

    Drug: MDNA11 · Drug: Pembrolizumab (KEYTRUDA®)

Interventions

  • DrugMDNA11

    Dose escalation/evaluation - MDNA11 will be administered, IV on a once every 2 weeks (Q2W) dosing schedule. Provisional dose cohorts for monotherapy dose escalation doses ranging from 0.003 to 0.6 (mg/kg) until determining the monotherapy Recommended Dose for Expansion (mRDE). Dose expansion - MDNA11 will be administered according to defined mRDE

    Also known as: Interleukin-2 (IL-2)-albumin

  • DrugPembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dose escalation/evaluation - MDNA11 will be administered in combination with pembrolizumab, IV. MDNA11 dose range to be evaluated in combination with pembrolizumab until determining the combination Recommended Dose for Expansion (cRDE). Dose expansion - MDNA11+ pembrolizumab will be administered according to defined cRDE

06

What researchers measure

Primary outcomes

  1. MDNA11 Recommended Dose for Expansion for monotherapy (mRDE) and Recommended Dose for Expansion for combination (cRDE)

    Evaluation of tolerability as measured by number of patients with dose limiting toxicities (DLTs)

    Time frame: 24 months

  2. Incidence of Treatment Related Adverse Events (TRAEs)

    Rate of TRAEs in patients with advanced solid tumors

    Time frame: 24 months

  3. Incidence of Treatment Emergent Adverse Events (TEAEs)

    Rate of TEAEs in patients with advanced solid tumors

    Time frame: 24 months

Secondary outcomes

  1. Pharmacokinetic characteristics on MDNA11 - Cmax (ug/mL)

    Maximum observed serum drug concentration

    Time frame: Up to 24 months

  2. Pharmacokinetic characteristics on MDNA11 - Tmax (h)

    Time to maximum observed serum drug concentration

    Time frame: Up to 24 months

  3. Pharmacokinetic characteristics on MDNA11 - AUClast (h.ug/mL)

    Area under the serum concentration vs time curve from time zero to the last measurable concentration

    Time frame: Up to 24 months

  4. Immunogenicity of MDNA11 (anti-drug antibodies)

    Incidence and persistence of anti-drug antibodies to MDNA11

    Time frame: Up to 24 months

  5. Pharmacodynamic effects of MDNA11

    Measurement of translational parameters - Flow cytometry analysis of immune cells in blood and serum measurements of cytokine levels

    Time frame: Up to 24 months

  6. Anti-tumor activity of MDNA11 (alone or in combination with CPI) - Overall Response Rate (ORR)

    Assessed by RECIST v1.1 and iRECIST; CR+PR/Evaluable N

    Time frame: Approximately 24 months

  7. Anti-tumor activity of MDNA11 (alone or in combination with CPI) - Disease Control Rate (DCR)

    CR+PR+SD/Evaluable N

    Time frame: Approximately 24 months

  8. Anti-tumor activity of MDNA11 (alone or in combination with CPI) - Progression Free Survival (PFS)

    Time from signing ICF to disease progression

    Time frame: Approximately 24 months

Other outcomes

  1. Analysis of immune characteristics of the tumor microenvironment

    Measured by change in Tumor Infiltrating Lymphocyte (TIL) levels

    Time frame: Up to 24 months

07

Study locations

25 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Oct 2028, 85 months after the start.

Of 71 industry-sponsored phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's planned 85 months is above that.

Counting every sponsor, half of 112 studies reached it within 64 months; a quarter within 45 and three quarters within 87.

Primary completion moved twice since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2028, last on Oct 30, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Dec 2026 → Oct 2028, last on Oct 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2021
First posted
Oct 21, 2021
StartActual
Aug 27, 2021
Primary completionEst.
Oct 20, 2028was Jun 2026
CompletionEst.
Oct 20, 2028was Dec 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 30, 2026
Sites
1 site added, 3 sites removed — first site in Switzerland. 12 sites changed recruiting status (9 now active, not recruiting, 3 now withdrawn)
Show 12 sites
  • Sharp Memorial Hospital · San Diego, United StatesRecruiting→Active, not recruiting
  • Providence Saint John's Health Center · Santa Monica, United StatesRecruiting→Active, not recruiting
  • Boca Raton Regional Hospital · Boca Raton, United StatesRecruiting→Active, not recruiting
  • Emory - Winship Cancer Institute · Atlanta, United StatesRecruiting→Active, not recruiting
  • Karmanos Cancer Institute · Detroit, United StatesRecruiting→Active, not recruiting
  • Scientia Clinical Research · Randwick, AustraliaRecruiting→Active, not recruiting
  • Macquarie University · Sydney, AustraliaRecruiting→Active, not recruiting
  • University of the Sunshine Coast · Buderim, AustraliaRecruiting→Active, not recruiting
  • Princess Margaret Cancer Center · Toronto, CanadaRecruiting→Active, not recruiting
  • The Catholic University of Korea St. Vincent Hospital · Suwon, South KoreaActive, not recruiting→Withdrawn
  • Hospital de la Santa Creu i Sant Pau · Barcelona, SpainRecruiting→Withdrawn
  • Hospital Universitario Central de Asturias (HUCA) · Oviedo, SpainRecruiting→Withdrawn
Show site
  • Hautkrebszentrum, Dermatologische Klinik Universitätsspital Zürich · Zurich, Switzerland
Show 3 removed
  • The Catholic University of Korea St. Vincent Hospital · Suwon, South Korea
  • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
  • Hospital Universitario Central de Asturias (HUCA) · Oviedo, Spain
across 2 updates, Oct 13, 2026 – Oct 30, 2026
Primary completion
Jun 30, 2026→Oct 20, 2028
moved 2 times, Oct 13, 2026 – Oct 30, 2026
Study completion
Dec 30, 2026→Oct 20, 2028
moved 2 times, Oct 13, 2026 – Oct 30, 2026
Enrollment
115→160
Oct 13, 2026
Show all 2 updates
  1. Oct 30, 2026
    Recruiting→Active, not recruiting
    3 sites removed
    Show 3 removed
    • The Catholic University of Korea St. Vincent Hospital · Suwon, South Korea
    • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
    • Hospital Universitario Central de Asturias (HUCA) · Oviedo, Spain
    Primary completion Nov 30, 2026→Oct 20, 2028
    Study completion Dec 30, 2028→Oct 20, 2028
    + 1 other change: contact details
  2. Oct 13, 2026
    1 site added — first site in Switzerland. 12 sites changed recruiting status (9 now active, not recruiting, 3 now withdrawn)
    Show 12 sites
    • Sharp Memorial Hospital · San Diego, United StatesRecruiting→Active, not recruiting
    • Providence Saint John's Health Center · Santa Monica, United StatesRecruiting→Active, not recruiting
    • Boca Raton Regional Hospital · Boca Raton, United StatesRecruiting→Active, not recruiting
    • Emory - Winship Cancer Institute · Atlanta, United StatesRecruiting→Active, not recruiting
    • Karmanos Cancer Institute · Detroit, United StatesRecruiting→Active, not recruiting
    • Scientia Clinical Research · Randwick, AustraliaRecruiting→Active, not recruiting
    • Macquarie University · Sydney, AustraliaRecruiting→Active, not recruiting
    • University of the Sunshine Coast · Buderim, AustraliaRecruiting→Active, not recruiting
    • Princess Margaret Cancer Center · Toronto, CanadaRecruiting→Active, not recruiting
    • The Catholic University of Korea St. Vincent Hospital · Suwon, South KoreaActive, not recruiting→Withdrawn
    • Hospital de la Santa Creu i Sant Pau · Barcelona, SpainRecruiting→Withdrawn
    • Hospital Universitario Central de Asturias (HUCA) · Oviedo, SpainRecruiting→Withdrawn
    Show site
    • Hautkrebszentrum, Dermatologische Klinik Universitätsspital Zürich · Zurich, Switzerland
    Primary completion Jun 30, 2026→Nov 30, 2026
    Study completion Dec 30, 2026→Dec 30, 2028
    Enrollment 115→160
    + 6 other changes: identifiers, verification date, registry dates, oversight details, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05086692
Lead sponsor
Medicenna Therapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 21, 2021
Start date
Aug 27, 2021
Primary completion
Oct 20, 2028 (estimated)
Completion
Oct 20, 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Nina Merchant
study director · Medicenna Therapeutics
Arash Yavari, MBBS
study chair · Medicenna Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion